In 2013, mutations in the calreticulin gene (CALR) were identified in two Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs), essential thrombocythemia (ET) and primary myelofibrosis (PMF)1,2. The gene discussed is CALR; the disease is myeloproliferative disorder.